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The discovery that somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs)
raised the exciting possibility of modeling diseases with patient-specific cells. Marchetto et al.
(2010) now use iPSC technology to generate, characterize, and treat an in vitro model for the autism
spectrum disorder Rett syndrome.Rett syndrome is a severe X-linked neuro-
developmental disorder that affects 1 in
10,000–20,000 girls worldwide, making it
one of the most common forms of mental
retardation in females (Percy and Lane,
2005). A seminal discovery by Huda
Zoghbi’s lab in 1999 identified a causative
link betweenmutations in themethyl-CpG
binding protein, MeCP2, and Rett syn-
drome (Amir et al., 1999), thus enabling
mechanistic studies andproviding a target
for potential treatments. Importantly,
restoration of MeCP2 function in a mouse
model of the disease reverses the neuro-
logical symptoms in adult mice (Guy
et al., 2007), raising the possibility that
this disorder may be treatable in humans.
Despite this progress, it remains unclear
how loss of MeCP2 function leads to
neurological defects, and no effective
pharmacological treatments have yet
been developed. A main limitation for
human studies and thus drug develop-
ment has been the inaccessibility of live
neurons from human patients. To circum-
vent this shortcoming, Marchetto and
colleagues (Marchetto et al., 2010 [this
issue of Cell]) use induced pluripotent
stem cells (iPSCs) to establish a human
cellular model for Rett syndrome that is
amenable to mechanistic studies and
drug screens.
To generate a human model of Rett
syndrome, Marchetto et al. (2010) isolate
fibroblasts from four female Rett patients
and five healthy control individuals
and then reprogram these fibroblasts
into iPSC lines (Figure 1). These cell
lines express the expected pluripotency
markers and give rise to cell types of allgerm layers in teratomas (solid tumors
derived from pluripotent cells), thus qual-
ifying these cell lines as bona fide pluripo-
tent cells. Given that hallmarks of Rett
syndrome include changes in neuronal
density and in brain size, the authors first
determine whether these phenotypes are
likely due to the abnormal proliferation
of neural progenitor cells derived from
iPSCs. Notably, they observe no overt
defects in the cell cycle of neural progen-
itor cells, consistent with the notion that
Rett is a disease of mature neurons.
In contrast to neural progenitor cells,
mature neurons derived from Rett iPSCs
do show defects in structure and function
when compared to neurons obtained from
control iPSCs or embryonic stem cells
(ESCs). For example, the authors detect
a significant reduction in the number
of synapses in glutamatergic neurons
derived from Rett iPSCs when compared
to neurons derived from either control
iPSCs or ESCs. This reduction is likely
the direct consequence of losing MeCP2
function, given that reducing the expres-
sion of MeCP2 in control ESCs produces
a similar defect whereas the reintroduc-
tion of wild-type MeCP2 into mutant cells
rescues the phenotype.
The authors further confirm MeCP2’s
role in regulating synapse formation by
showing that overexpression of MeCP2
in control iPSCs leads to an increase in
glutamatergic synapse numbers. These
results are in accordance with observa-
tions from mouse models in which the
loss or overexpression of MeCP2 leads
to a respective decrease or increase of
glutamatergic synapses (Chao et al.,Cell 143, N2007). In further agreement with research
performed with mouse cells (Chen et al.,
2001; Guy et al., 2001) and on human
autopsies, neurons derived from Rett
iPSCs are smaller in size and have fewer
dendritic spines when compared to
control iPSC and ESC neurons.
Importantly, neurons derived from Rett
iPSCs are also functionally impaired
when compared to neurons derived from
control iPSCs. Specifically, neurons
derived from Rett iPSCs exhibit a reduc-
tion in the transient rise of intracellular
calcium levels typical of active synapses.
They also show a decrease in the
frequency and amplitude of spontaneous
excitatory and inhibitory postsynaptic
currents when compared to control cells.
Together, these findings provide compel-
ling evidence that molecular and func-
tional defects found in Rett syndrome
patients can be recapitulated in iPSC-
derived neurons.
Given the reversibility of the Rett
phenotype in mouse, Marchetto et al.
(2010) then askwhether they could rescue
their in vitro phenotype using candidate
drugs. First, they examine the effects of
insulin-like growth factor 1 (IGF1), which
had previously been shown to partially
rescue Rett symptoms in Mecp2-defi-
cient mice (Tropea et al., 2009). Indeed,
treating neurons derived from human
Rett iPSCs with this growth factor
increases the number of glutamatergic
synapses.
Because the majority of MeCP2 muta-
tions create premature stop codons in
the gene (i.e., nonsense mutations), the
authors also test the effect of the drugovember 12, 2010 ª2010 Elsevier Inc. 499
Figure 1. Using iPSCs to Model Rett Syndrome In Vitro
Mutations in themethyl-CpG binding protein (MeCP2) gene cause the neurodevelopmental disorder Rett
syndrome. Marchetto et al. (2010) isolate fibroblasts from Rett patients withMeCP2mutations. They then
reprogram these cells into induced pluripotent stem cells (iPSCs) by the exogenous expression of the tran-
scription factorsOct4, Sox2,Klf4, and c-Myc. These Rett iPSCs can then differentiate into neurons in vitro,
recapitulating several of the defects found in Rett syndrome patients and in animal models of the disease.
These defects can be partially reversed by candidate drugs, suggesting that this disease model will facil-
itate large-scale drug screens and future mechanistic studies of Rett syndrome.gentamicin, which facilitates ribosomal
readthrough of stop codons. Following
treatment with low doses of gentamicin,
Rett neurons harboring nonsense muta-
tions in theMeCP2 gene express elevated
levels of MeCP2 protein and display
a striking increase of glutamatergic
synapses, reaching levels similar to those
seen in control neurons. Whether IGF1 or
gentamicin treatment leads to a functional
recovery of neurons, however, remains
unexplored in this study. In summary,
these results show that previously identi-
fied drugs are effective on neurons
derived from Rett iPSCs and thus validate
the use of large-scale drug screens to
identify new and more effective com-
pounds that could ameliorate the symp-
toms of Rett.
Given the recent recognition that
mouse iPSCs can exhibit molecular and
functional differences compared with
mouse ESCs (Stadtfeld and Hochedlin-
ger, 2010), it will be important to ensure500 Cell 143, November 12, 2010 ª2010 Elsethat any cell culture disease model is an
accurate representation of its in vivo
counterpart rather than an artifact of the
reprogramming procedure. In that regard,
data presented by Marchetto and
colleagues for their Rett syndrome model
agreewell with what is known frommouse
models of Rett syndrome and post-
mortem analyses in humans. However,
the observation by the authors that differ-
entiated neurons derived from Rett iPSCs
exhibit a severe skewing of X chromo-
some inactivation—meaning that one
copy of the X chromosome is more likely
to undergo inactivation than the other—
remains unexplained. This observation is
of particular relevance because MeCP2
is an X-linked gene and patients’ cells
in vivo aremosaic for theMeCP2mutation
due to random X chromosome inactiva-
tion. One possible explanation for the
skewing of X inactivation in vitro is that
the previously inactive X chromosome in
Rett fibroblasts does not fully reactivatevier Inc.in iPSCs and remains inactive in iPSC-
derived neurons. Indeed, a recent study
on skewed X chromosome inactivation in
human iPSCs by Kathrin Plath’s lab is
consistent with this interpretation (Tchieu
et al., 2010). If the skewing reflects incom-
plete reactivation, then the studies per-
formed by Marchetto and colleagues
likely relied exclusively on iPSC clones
derived from Rett fibroblasts that had
inactivated the wild-type MeCP2 allele.
Thus, to harness the power of cell culture
disease models, future work will need to
further explore the differences between
iPSCs and ESCs.
The ability to produce disease-specific
differentiated cells is one of the major
promises of iPSC technology because it
holds the potential for disease modeling,
drug development, and ultimately cell
therapy. Themodel of Rett syndrome pre-
sented by Marchetto and colleagues is
not only an additional proof of principle
that human iPSCs may be useful in drug
development but also a promising oppor-
tunity to gain insights into the pathology of
Rett syndrome in live human neurons.
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